TMEM132D

Summary

TMEM132D (transmembrane protein 132D, HGNC:29411) is a protein-coding gene on chromosome 12q24.33, encoding Transmembrane protein 132D (Q14C87). Regulate neuronals morphology via inhibition of the WAVE regulatory complex (WCR), a complex that controls F-actin cytoskeletal dynamics.

Predicted to be located in membrane.

Source: NCBI Gene 121256 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability (Limited, GenCC)
• GWAS associations: 20
• Clinical variants (ClinVar): 216 total
• MANE Select transcript: NM_133448

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29411
Approved symbol	TMEM132D
Name	transmembrane protein 132D
Location	12q24.33
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1944, MOLT, PPP1R153
Ensembl gene	ENSG00000151952
Ensembl biotype	protein_coding
OMIM	611257
Entrez	121256

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000389441, ENST00000422113

RefSeq mRNA: 1 — MANE Select: NM_133448 NM_133448

CCDS: CCDS9266

Canonical transcript exons

ENST00000422113 — 9 exons

Exon	Start	End
ENSE00001002597	129081759	129082032
ENSE00001203227	129071726	129075059
ENSE00001294780	129699810	129700698
ENSE00001307778	129337634	129337817
ENSE00001314726	129078534	129078725
ENSE00001325482	129531059	129531205
ENSE00001367158	129903261	129904025
ENSE00001505858	129209520	129209663
ENSE00002363476	129084497	129084702

Expression profiles

Bgee: expression breadth broad, 79 present calls, max score 90.03.

FANTOM5 (CAGE): breadth broad, TPM avg 0.8546 / max 59.6868, expressed in 244 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
134146	0.4161	156
134145	0.3472	155
134144	0.0913	48

Top tissues by expression

227 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	90.03	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.31	gold quality
Brodmann (1909) area 46	UBERON:0006483	83.64	gold quality
endothelial cell	CL:0000115	83.56	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.31	gold quality
primary visual cortex	UBERON:0002436	80.70	gold quality
prefrontal cortex	UBERON:0000451	80.31	gold quality
ventricular zone	UBERON:0003053	79.78	gold quality
islet of Langerhans	UBERON:0000006	78.56	gold quality
superior frontal gyrus	UBERON:0002661	77.89	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	77.58	gold quality
occipital lobe	UBERON:0002021	77.12	gold quality
frontal cortex	UBERON:0001870	77.06	gold quality
neocortex	UBERON:0001950	76.19	gold quality
Brodmann (1909) area 9	UBERON:0013540	74.72	gold quality
ganglionic eminence	UBERON:0004023	74.14	gold quality
cerebral cortex	UBERON:0000956	74.06	gold quality
anterior cingulate cortex	UBERON:0009835	73.53	gold quality
entorhinal cortex	UBERON:0002728	72.78	gold quality
postcentral gyrus	UBERON:0002581	72.53	gold quality
right frontal lobe	UBERON:0002810	72.43	gold quality
parietal lobe	UBERON:0001872	72.07	gold quality
tibialis anterior	UBERON:0001385	71.45	silver quality
pancreatic ductal cell	CL:0002079	70.75	gold quality
temporal lobe	UBERON:0001871	69.65	gold quality
forebrain	UBERON:0001890	68.01	gold quality
nucleus accumbens	UBERON:0001882	67.07	gold quality
amygdala	UBERON:0001876	66.90	gold quality
putamen	UBERON:0001874	65.29	gold quality
brain	UBERON:0000955	64.61	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-180759	yes	1918.71
E-HCAD-35	yes	94.89
E-ANND-3	yes	3.76

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

90 targeting TMEM132D, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785

Literature-anchored findings (GeneRIF, showing 8)

• TMEM132D may be an important new candidate gene for PD as well as more generally for anxiety-related behavior. (PMID:20368705)
• We found no genome-wide statistically significant associations but identified several plausible candidate genes among findings at p < 5E-05: TMEM132D, LRRC7, SEMA3A, ALK, and STIP1. (PMID:21784300)
• data suggest that not only common but also putatively functional and/or rare variants within TMEM132D might contribute to the risk to develop anxiety disorders (PMID:22911938)
• TMEM132D was first identified as a possible candidate gene for panic disorder in a genome-wide association study conducted at the Max Planck Institute of Psychiatry in Munich. (PMID:22948381)
• Enhanced amygdala gray matter volumes and anxiety-related (but not panic-specific) personality profiles are found in healthy normal carriers of the rs11060369 AA TMEM132D genotype. (PMID:24495968)
• TMEM132D, COMT and GABRA6 gene polymorphisms may influence susceptibility to panic disorder(PD) and major depressive disorder(MDD)in Japanese adults; these variants may increase vulnerability to PD by modulating oligodendrocytes and GABA and dopaminergic functions in related brain regions, altering neuronal processing of anxiety-related emotionl signals (PMID:25974322)
• Thus, GPC6 and TMEM132D may serve as predictors of CD8+ T-lymphocyte infiltration and as favorable prognostic markers in early stage ovarian cancer with important consequences for diagnosis. (PMID:26448945)
• TMEM132D and VIPR2 Polymorphisms as Genetic Risk Loci for Retinal Detachment: A Genome-Wide Association Study and Polygenic Risk Score Analysis. (PMID:37695605)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	TMEM132D	ENSDARG00000102759
mus_musculus	Tmem132d	ENSMUSG00000034310
rattus_norvegicus	Tmem132d	ENSRNOG00000008447
drosophila_melanogaster	dtn	FBGN0262730
caenorhabditis_elegans		WBGENE00022175

Paralogs (4): TMEM132A (ENSG00000006118), TMEM132B (ENSG00000139364), TMEM132C (ENSG00000181234), TMEM132E (ENSG00000181291)

Protein

Protein identifiers

Transmembrane protein 132D — Q14C87 (reviewed: Q14C87)

Alternative names: Mature oligodendrocytes transmembrane protein

All UniProt accessions (1): Q14C87

UniProt curated annotations — full annotation on UniProt →

Function. Regulate neuronals morphology via inhibition of the WAVE regulatory complex (WCR), a complex that controls F-actin cytoskeletal dynamics.

Subunit / interactions. Interacts (via C-terminus) with NCKAP.

Subcellular location. Membrane.

Tissue specificity. Expressed in mature oligodendrocytes. Detected in the brain, lung, pancreas and testis. Highly expressed in mature neurons of the adult nervous system.

Similarity. Belongs to the TMEM132 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14C87-1	1	yes
Q14C87-2	2

RefSeq proteins (1): NP_597705* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026307	TMEM132	Family
IPR031435	TMEM132_N	Domain
IPR031436	TMEM132_C	Domain
IPR031437	Ig_TMEM132_4th	Domain
IPR055421	TMEM132_3rd	Domain
IPR055422	Ig_TMEM132_2nd	Domain
IPR055423	Ig_TMEM132_5th	Domain
IPR055424	Ig_TMEM132_6th	Domain

Pfam: PF15705, PF15706, PF16070, PF23039, PF23481, PF23486, PF23487

UniProt features (15 total): sequence variant 3, sequence conflict 2, topological domain 2, splice variant 2, signal peptide 1, chain 1, transmembrane region 1, region of interest 1, compositionally biased region 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14C87-F1	70.52	0.35

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 505

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 42 (showing top): ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, chr12q24, MEISSNER_NPC_HCP_WITH_H3K4ME2, PILON_KLF1_TARGETS_UP, HMGA1_TARGET_GENES, MIR4668_5P, MIR6875_3P, MIR4766_5P, MIR3978, MIR139_5P, MIR4478, MIR6884_5P, MIR6730_5P, MIR485_5P, MIR4659B_5P

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

816 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM132D	TCERG1L	Q5VWI1	484
TMEM132D	CCDC92	Q53HC0	461
TMEM132D	TAFA5	Q7Z5A7	460
TMEM132D	POLN	Q7Z5Q5	456
TMEM132D	GLT1D1	Q96MS3	424
TMEM132D	OR4N5	Q8IXE1	392
TMEM132D	LYST	Q99698	387
TMEM132D	FZD10	Q9ULW2	379
TMEM132D	ENOPH1	Q9UHY7	378
TMEM132D	RBM20	Q5T481	373
TMEM132D	CDH10	Q9Y6N8	370
TMEM132D	OR4K14	Q8NGD5	370
TMEM132D	HPS6	Q86YV9	364
TMEM132D	PPM1F	P49593	360
TMEM132D	VWC2L	B2RUY7	357

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TMEM132D	PPP1CA	psi-mi:“MI:0915”(physical association)	0.540
PPP1CA	TMEM132D	psi-mi:“MI:0407”(direct interaction)	0.540

BioGRID (75): NCKAP1 (Two-hybrid), RNF2 (Two-hybrid), HDAC2 (Two-hybrid), NDUFS5 (Two-hybrid), PLSCR2 (Two-hybrid), STK39 (Two-hybrid), HOXA9 (Two-hybrid), TMED7-TICAM2 (Two-hybrid), PTPRD (Two-hybrid), CD59 (Two-hybrid), NAMPT (Two-hybrid), ANKRD36 (Two-hybrid), PNISR (Two-hybrid), CMPK1 (Two-hybrid), UMOD (Two-hybrid)

ESM2 similar proteins: A2VDP6, A4D0V7, B1WB06, F1N2K1, O43548, P06802, P15396, P22413, P50127, P79949, P97259, Q05004, Q08834, Q08BN9, Q09328, Q14C87, Q14DG7, Q2TU62, Q3L7M0, Q3U095, Q52KP5, Q5R748, Q5RCA5, Q5XI89, Q5ZLK4, Q6AX23, Q6DNG6, Q6UWF7, Q6ZXA0, Q76HP2, Q76HP3, Q86UX2, Q8BG22, Q8C7K6, Q8K1B9, Q8N323, Q8NCG5, Q8NHY0, Q8R4G6, Q8VI38

Diamond homologs: L7VG99, Q14C87, Q14DG7, Q24JP5, Q6IEE6, Q6IEE7, Q76HP2, Q76HP3, Q80WF4, Q8CEF9, Q8N3T6, Q922P8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

216 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	163
Likely benign	34
Benign	12

Top pathogenic / likely-pathogenic (0)

SpliceAI

3999 predictions. Top by Δscore:

Variant	Effect	Δscore
12:129081753:TTTTA:T	donor_loss	1.0000
12:129081754:TTTA:T	donor_loss	1.0000
12:129081755:TTAC:T	donor_loss	1.0000
12:129081756:TACCT:T	donor_loss	1.0000
12:129081757:ACCT:A	donor_loss	1.0000
12:129082028:CAGGC:C	acceptor_gain	1.0000
12:129082031:GCCT:G	acceptor_loss	1.0000
12:129082033:C:CC	acceptor_gain	1.0000
12:129082033:CTGTG:C	acceptor_loss	1.0000
12:129082034:T:A	acceptor_loss	1.0000
12:129084495:A:C	donor_loss	1.0000
12:129084495:ACCT:A	donor_gain	1.0000
12:129084496:CCTC:C	donor_gain	1.0000
12:129084498:T:TA	donor_gain	1.0000
12:129084698:GAAAC:G	acceptor_gain	1.0000
12:129084699:AAAC:A	acceptor_gain	1.0000
12:129084700:AAC:A	acceptor_gain	1.0000
12:129084700:AACC:A	acceptor_loss	1.0000
12:129084701:AC:A	acceptor_gain	1.0000
12:129084701:ACC:A	acceptor_loss	1.0000
12:129084702:CCTG:C	acceptor_gain	1.0000
12:129084703:C:CC	acceptor_gain	1.0000
12:129084703:C:CG	acceptor_loss	1.0000
12:129084704:T:G	acceptor_loss	1.0000
12:129084705:G:C	acceptor_gain	1.0000
12:129084713:G:C	acceptor_gain	1.0000
12:129084713:G:GC	acceptor_gain	1.0000
12:129337630:TTA:T	donor_loss	1.0000
12:129337632:A:AC	donor_gain	1.0000
12:129337632:ACCA:A	donor_loss	1.0000

AlphaMissense

7272 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:129084525:A:G	W541R	0.999
12:129084525:A:T	W541R	0.999
12:129337732:A:G	W401R	0.999
12:129337732:A:T	W401R	0.999
12:129074034:A:C	F1047L	0.998
12:129074034:A:T	F1047L	0.998
12:129074036:A:G	F1047L	0.998
12:129074373:G:C	F934L	0.998
12:129074373:G:T	F934L	0.998
12:129074375:A:G	F934L	0.998
12:129337730:C:A	W401C	0.997
12:129337730:C:G	W401C	0.997
12:129699819:A:G	F320S	0.997
12:129699852:A:T	V309D	0.997
12:129074394:G:C	F927L	0.996
12:129074394:G:T	F927L	0.996
12:129074396:A:G	F927L	0.996
12:129700263:G:T	A172D	0.996
12:129074035:A:G	F1047S	0.995
12:129074374:A:G	F934S	0.995
12:129074386:G:T	A930D	0.995
12:129074393:A:G	C928R	0.995
12:129084523:C:A	W541C	0.995
12:129084523:C:G	W541C	0.995
12:129084674:A:T	V491D	0.995
12:129209549:A:G	C472R	0.995
12:129209646:G:C	N439K	0.995
12:129209646:G:T	N439K	0.995
12:129337737:A:T	V399D	0.995
12:129531145:C:A	W343C	0.995

dbSNP variants (sampled 300 via entrez): RS1000005170 (12:129632660 T>C), RS1000026774 (12:129447959 T>A), RS1000034084 (12:129487600 A>G,T), RS1000039129 (12:129517048 G>A), RS1000042742 (12:129769022 T>C), RS1000045014 (12:129742810 A>C,G), RS1000045049 (12:129194689 G>T), RS1000048684 (12:129629492 C>G,T), RS1000051160 (12:129119173 G>T), RS1000051758 (12:129339596 A>G), RS1000061877 (12:129421631 T>C), RS1000063599 (12:129756726 G>C), RS1000064936 (12:129853024 C>G,T), RS1000068090 (12:129333539 A>G), RS1000076273 (12:129743102 C>G)

Disease associations

OMIM: gene MIM:611257 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability	Limited	Autosomal recessive

Mondo (2): primary ovarian failure (MONDO:0005387), intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST001762_189	Obesity-related traits	5.000000e-07
GCST001921_3	Heart rate	9.000000e-06
GCST002696_11	Anxiety disorder	5.000000e-06
GCST002812_3	Schizophrenia (inflammation and infection response interaction)	8.000000e-06
GCST003075_12	Cognitive decline rate in late mild cognitive impairment	1.000000e-08
GCST003983_41	Male-pattern baldness	4.000000e-08
GCST004125_19	Type 2 diabetes (age of onset)	4.000000e-06
GCST004250_23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	2.000000e-06
GCST004863_65	Mosquito bite size	4.000000e-06
GCST005023_28	Initial pursuit acceleration	6.000000e-07
GCST005212_2	Asthma	5.000000e-06
GCST006585_1320	Blood protein levels	1.000000e-18
GCST007624_3	Positive urgency	5.000000e-07
GCST007831_4	Anti-thyroglobulin (TgAb) levels in Hashimoto’s thyroiditis	1.000000e-06
GCST007851_7	Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto’s thyroiditis	6.000000e-06
GCST008154_23	Trunk fat mass	3.000000e-06
GCST008157_48	Body fat mass	1.000000e-06
GCST009422_2	Retinal venular tortuosity	3.000000e-06
GCST012034_8	Sleep (1/2-day periodicity)	2.000000e-08
GCST012048_25	Triglyceride levels	8.000000e-09

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004730	hormone measurement
EFO:0007050	HSV1 seropositivity
EFO:0007710	cognitive decline measurement
EFO:0007965	response to combination chemotherapy
EFO:0008378	mosquito bite reaction size measurement
EFO:0008434	initial pursuit acceleration
EFO:0006946	behavioural disinhibition measurement
EFO:0010554	retinal vasculature measurement
EFO:0004530	triglyceride measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
mercuric bromide	decreases expression, affects cotreatment	2
Resveratrol	affects cotreatment, decreases expression	2
Benzo(a)pyrene	increases methylation, affects methylation	2
Valproic Acid	increases expression, increases methylation	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
bisphenol F	affects cotreatment, decreases methylation	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects methylation, affects cotreatment	1
terbufos	increases methylation	1
benzo(e)pyrene	affects methylation	1
aflatoxin B2	decreases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Decitabine	affects expression	1
Fulvestrant	affects cotreatment, affects methylation, decreases methylation	1
Cisplatin	affects expression	1
Copper	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Fonofos	increases methylation	1
Methapyrilene	affects methylation	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	increases expression	1
1-Naphthylamine	affects response to substance	1
Aflatoxin B1	decreases methylation	1
Asbestos, Serpentine	decreases methylation	1

Clinical trials (associated diseases)

272 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability